Sun Pharma receives warning letter from FDA for deficiencies at Halol facility

Shares in Indian drug maker Sun Pharmaceutical (BOM: 524715) fell nearly 4.6% on the Bombay Stock Exchange after the company said it has received a warning letter from the US Food and Drug Administration regarding quality control issues at its manufacturing facility in Halol, Gujarat.

The stock has dropped over 10% since the start of 2015.

Dilip Shanghvi, managing director of Sun Pharma, said: “While our team is working hard to ensure that the commitments made to the US FDA in September 2014 are fully completed, we will continue to cooperate with the US FDA and undertake any additional steps necessary to ensure that the US Agency is completely satisfied with our remediation of the Halol facility. Sun Pharma has always ensured that its products are safe and effective and there is no doubt on the safety of our products in the market. We are pledged to being cGMP compliant and are committed to continuing to supply our customers and patients across the world with quality products that meet all specifications.”